Pharmaceuticals News

Cronos acquires CanAdelaar for a base purchase price of €57.5 million plus cash earnout of 0.5x Normalized EBITDA1 in 2026 and 2027 Establishes Cronos’ European platform with #1 market share2 in the...

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No Thromboembolic Events Were Reported for ADMA IVIG...

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical...

Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16...

RECLAIM-II evaluates Salvia’s purpose-built neuromodulation system for migraine as a potential new preventive treatment for adults with resistant migraine. Eindhoven, the Netherlands and Newnan,...

In de RECLAIM-II-studie wordt Salvia’s speciaal voor migraine ontwikkelde therapie onderzocht als preventieve behandeling voor volwassenen met moeilijk te behandelen migraine. EINDHOVEN, 15 oktober...

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for...

R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026

Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors  Proceeds to advance MC2 receptor...